MedTrace Logo

NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis

NCT00206180 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2009-03-26

No results posted yet for this study

Summary

The purpose of this study is to decide if controlling stomach acid is related to healing of erosive esophagitis after treatment with esomeprazole magnesium (NEXIUM®) 10 mg and 40 mg once daily.

Conditions

  • Erosive Esophagitis
  • Reflux Esophagitis
  • Gastroesophageal Reflux Disease

Interventions

DRUG

esomeprazole magnesium (oral medication)

Sponsors & Collaborators

Principal Investigators

  • Nexium Medical Science Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Completion
2005-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00206180 on ClinicalTrials.gov